Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

被引:42
作者
Qazi, Asif Khurshid [1 ]
Hussain, Aashiq [1 ]
Hamid, Abid [1 ]
Qurishi, Yasrib [1 ]
Majeed, Rabiya [1 ]
Ahmad, Mudassier [1 ]
Najar, Rauf Ahmad [1 ]
Bhat, Javeed Ahmad [1 ]
Singh, Shashank Kumar [1 ]
Zargar, Mohmmad Afzal [2 ]
Ali, Shakir [3 ]
Saxena, Ajit Kumar [1 ]
机构
[1] CSIR Indian Inst Integrat Med, Canc Pharmacol Div, Jammu 180001, India
[2] Univ Kashmir, Dept Biochem, Srinagar 190001, Jammu & Kashmir, India
[3] Jamia Hamdard, Dept Biochem, New Delhi 110062, India
关键词
Anticancer target; cancer; inhibitors; PI3K-Akt-mTOR; Signaling; therapy; translation; II PHOSPHOINOSITIDE 3-KINASE; PLECKSTRIN HOMOLOGY DOMAIN; BREAST-CANCER; CELL-MIGRATION; DEPENDENT MECHANISM; ANTITUMOR-ACTIVITY; KINASE INHIBITORS; TUMOR SUPPRESSION; LIPID KINASE; PATHWAY;
D O I
10.2174/1871520613666131125123241
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.
引用
收藏
页码:1552 / 1564
页数:13
相关论文
共 69 条
[1]
[Anonymous], AACR M
[2]
[Anonymous], AACR M
[3]
A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells [J].
Bénistant, C ;
Chapuis, H ;
Roche, S .
ONCOGENE, 2000, 19 (44) :5083-5090
[4]
Bernstein HG, 1998, CELL MOL BIOL, V44, P973
[5]
Relationships between Rap1b, affinity modulation of integrin αIIbβ3, and the actin cytoskeleton [J].
Bertoni, A ;
Tadokoro, S ;
Eto, K ;
Pampori, N ;
Parise, LV ;
White, GC ;
Shattil, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25715-25721
[6]
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase [J].
Byfield, MP ;
Murray, JT ;
Backer, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (38) :33076-33082
[7]
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[8]
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? [J].
Carden, Craig P. ;
Sarker, Debashis ;
Postel-Vinay, Sophie ;
Yap, Timothy A. ;
Attard, Gerthardt ;
Banerji, Udai ;
Garrett, Michelle D. ;
Thomas, George V. ;
Workman, Paul ;
Kaye, Stan B. ;
de Bono, Johann S. .
DRUG DISCOVERY TODAY, 2010, 15 (3-4) :88-97
[9]
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer [J].
Carpten, John D. ;
Faber, Andrew L. ;
Horn, Candice ;
Donoho, Gregory P. ;
Briggs, Stephen L. ;
Robbins, Christiane M. ;
Hostetter, Galen ;
Boguslawski, Sophie ;
Moses, Tracy Y. ;
Savage, Stephanie ;
Uhlik, Mark ;
Lin, Aimin ;
Du, Jian ;
Qian, Yue-Wei ;
Zeckner, Douglas J. ;
Tucker-Kellogg, Greg ;
Touchman, Jeffrey ;
Patel, Ketan ;
Mousses, Spyro ;
Bittner, Michael ;
Schevitz, Richard ;
Lai, Mei-Huei T. ;
Blanchard, Kerry L. ;
Thomas, James E. .
NATURE, 2007, 448 (7152) :439-U1
[10]
The PTEN-PI3K pathway: of feedbacks and cross-talks [J].
Carracedo, A. ;
Pandolfi, P. P. .
ONCOGENE, 2008, 27 (41) :5527-5541